Dear manoj kumar valluru,
Last week the Canadian company Sernova was issued a patent covering the use of Sertoli cells to deliver essentially any gene in vivo (#7,399,751) without evoking an immune response. Given that the company already has clinical proof of concept data on its lead product, Sertolin, for treatment of Type I Diabetes, this will be an interesting one to watch. Speaking of immunology, a very unorthodox approach to treating neural injury was presented in a patent (#7,399,740) covering a peptide polymer that INHIBITS T regulatory cells. Angioblast Systems scored nicely getting a key patent on its mesenchymal precursor cell (#7,399,632).
An interesting news item, Habib's group from England reported that injection of 9 patients with autologous expanded CD34s had clinical improvement...but people (a certain scientist from Stanford) say that CD34s only make blood...how is this possible !?!? (we are being ironic).
The Stem Cell Meeting, to be held in San Francisco on September 16-17, 2008, is returning for its 3rd year. This conference will examine the up to date most critical scientific, policy and business issues facing stem cell research, medicine and investment. In collaboration with the leaders of the City of San Francisco and the California Institute of Regenerative Medicine, it brings together an international assembly of scientists, clinicians, policymakers and business leaders who share their vision and passion for the life sciences’ most promising field.
This Stem Cell Meeting is the premier international event bringing together world-renowned scientists at the frontier of embryonic and adult stem cell research with decision-makers and thought leaders in policy, ethics, patient advocacy, finance, business, and media to explore the challenge and promise of stem cell research and the compelling potential of emerging therapies.
StemCellPatents.com is proud to be a supporter of the The Stem Cell Meeting.
|
|
|
|
Thanks again for your help in supporting StemCellPatents.com.
We welcome your comments! Tell us here.